hello. i m victor blackwell. welcome to cnn newsroom. i m alisyn camerota. we begin with the fight for evidence in the investigations of the january 6th attack on the capitol. the washington post reports that more texts are missing, this time from president trump s senior homeland security officials related to the days surrounding the riot. now it s more than just the secret service that can not produce critical texts connected to the trump supporters who tried to overturn joe biden s win. we re also learning about the latest moves from the justice department as investigators pursue interviews with top officials from the trump administration. cnn is exclusively reporting that prosecutors are preparing for a major court battle on executive privilege. it s the clearest sign yet that federal investigators are focusing on trump s actions and his attempts to prevent the transfer of power to joe biden. trump s former chief of staff, nick mulvaney, who testified yesterday, s
Immunogenicity of BA 5 Bivalent mRNA Vaccine Boosters nejm.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nejm.org Daily Mail and Mail on Sunday newspapers.
prevents severe symptoms, hospitalization. is that the same with the monkeypox vaccine, that you can still get it but not the worst of it, or does it stop transmission? well, remember, victor, this drug was approved on the basis of immunological bridging, meaning that it wasn t actually my understanding is it was approved in 2019 for both smallpox and monkeypox, the vaccine, on the basis of immune parameters, levels of neutralizing antibody, t-cell responses. so i don t think we fully understand all of the performance features of the vaccine at this point. those studies are still under way and there s going to be a need to continue those studies. but we do expect it to be highly effective and the advantage of this new vaccine is it s a non-replicating virus which is non-replicating, and that s why
Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.
/PRNewswire/ Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, today announced that the Company.